Kindred Biosciences is a development-stage biopharmaceutical company focused on saving and improving the lives of pets. The Company's core strategy is to identify compounds and targets that have already demonstrated safety and efficacy in humans and to develop therapeutics based on these validated compounds and targets for pets, primarily dogs, cats, and horses. Its lead product candidates are the intravenous, or IV, form of Zimeta (dipyrone injection), previously known as KIND-012, for the control of pyrexia (fever) in horses and Mirataz (mirtazapine transdermal ointment), formerly known as KIND-010, for management of weight loss in cats. In addition, the Company has other product candidates, including several biologics, in various stages of development.

Type
Public
HQ
Burlingame, US
Founded
2013
Size (employees)
41 (est)
Kindred Biosciences was founded in 2013 and is headquartered in Burlingame, US
Report incorrect company information

Key People/Management at Kindred Biosciences

Richard Chin

Richard Chin

Founder and Chief Executive Officer
Denise Bevers

Denise Bevers

Founder and Chief Operating Officer
Hangjun Zhan

Hangjun Zhan

Chief Scientific Officer
Wendy Wee

Wendy Wee

CFO
Karen Greenwood

Karen Greenwood

Vice President of Project Management
Jenna Hahn

Jenna Hahn

Senior Director, Commercial
Show more

Kindred Biosciences Office Locations

Kindred Biosciences has an office in Burlingame
Burlingame, US (HQ)
200 1555 Old Bayshore Hwy
Show all (1)
Report incorrect company information

Kindred Biosciences Financials and Metrics

Kindred Biosciences Financials

USD

Net income (Q1, 2018)

(10 m)

EBIT (Q1, 2018)

(10.2 m)

Market capitalization (14-Jun-2018)

324.3 m

Closing share price (14-Jun-2018)

11.5

Cash (31-Mar-2018)

44.5 m
Kindred Biosciences's current market capitalization is $324.3 m.
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017

General and administrative expense

2.4 m14 m

R&D expense

3.5 m17.7 m

Operating expense total

5.9 m31.7 m

EBIT

(5.9 m)(31.7 m)
Quarterly
USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

General and administrative expense

1.9 m2.1 m2 m1.9 m2 m2.8 m3.1 m4.9 m

R&D expense

5 m5 m3.4 m3.2 m3.8 m3.8 m3.9 m5.3 m

Operating expense total

6.9 m7.1 m6.1 m5 m5.8 m6.6 m6.9 m10.2 m

EBIT

(6.9 m)(7.1 m)(6.1 m)(5 m)(5.8 m)(6.6 m)(6.9 m)(10.2 m)
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017

Cash

13 m20 m6.7 m34.8 m

Inventories

1.9 m1.8 m

Current Assets

101.5 m73.8 m58 m81.8 m

PP&E

394 k1.2 m2.4 m7.5 m
Quarterly
USDQ2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

Cash

16 m13.3 m19.9 m36.9 m44.5 m

Accounts Receivable

2.1 m492 k

Current Assets

62.1 m61.4 m68.4 m75.3 m72.2 m

PP&E

1.7 m1.8 m2.6 m2.6 m7.9 m
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(120 k)(27.1 m)(5.8 m)(30.9 m)

Depreciation and Amortization

146 k155 k475 k

Inventories

(14.1 m)16 m(37.9 m)

Accounts Payable

6 k30 k(710 k)1.3 m
Quarterly
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q1, 2018

Net Income

(6.9 m)(7.1 m)(6.1 m)(4.9 m)(5.7 m)(6.5 m)(10 m)

Depreciation and Amortization

144 k

Accounts Payable

347 k1.1 m285 k567 k229 k690 k994 k(1.2 m)

Cash From Operating Activities

(11.2 m)
USDY, 2018

Financial Leverage

1.1 x
Show all financial metrics
Report incorrect company information

Kindred Biosciences Online and Social Media Presence

Embed Graph
Report incorrect company information

Kindred Biosciences News and Updates

Report incorrect company information